Ajanta Pharma Limited (NSE:AJANTPHARM)
India · Delayed Price · Currency is INR | Market Cap | 415.66B +29.1% |
| Revenue (ttm) | 62.17B +25.0% |
| Net Income | 12.63B +29.7% |
| EPS | 101.02 +29.6% |
| Shares Out | 124.94M |
| PE Ratio | 32.93 |
| Forward PE | 30.20 |
| Dividend | 28.00 (0.84%) |
| Ex-Dividend Date | Aug 5, 2026 |
| Volume | 110,462 |
| Open | 3,310.00 |
| Previous Close | 3,319.60 |
| Day's Range | 3,285.00 - 3,362.00 |
| 52-Week Range | 2,445.80 - 3,796.00 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 3,865.77 (+16.19%) |
| Earnings Date | Oct 30, 2026 |
About Ajanta Pharma
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management... [Read more]
Financial Performance
In fiscal year 2026, Ajanta Pharma's revenue was 54.53 billion, an increase of 17.31% compared to the previous year's 46.48 billion. Earnings were 10.56 billion, an increase of 14.73%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for AJANTPHARM stock is "Buy." The 12-month stock price target is ₹3,866, which is an increase of 16.19% from the latest price.
News
Ajanta Pharma Transcript: Q2 26/27
Q2 revenue grew 33% and H1 revenue 29%, with gains across all businesses. FY27 growth guidance remains high teens, though U.S. competition and normalization of institutional sales are expected to soften H2.
Ajanta Pharma Slides: Q2 2027
Ajanta Pharma has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 30, 2026.
Ajanta Pharma Quarterly report: Q2 2027
Ajanta Pharma has published its Q2 2027 quarterly earnings report on October 30, 2026.
Ajanta Pharma Transcript: Q1 26/27
Revenue grew 25% YoY with profit after tax up 31%, driven by strong India, Africa, and U.S. performance. Asia sales declined due to geopolitical disruptions, but recovery is expected from Q2. Guidance remains robust across segments, with high double-digit growth in Africa and mid-teens in India and Asia.
Ajanta Pharma Slides: Q1 2027
Ajanta Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Ajanta Pharma Quarterly report: Q1 2027
Ajanta Pharma has published its Q1 2027 quarterly earnings report on July 30, 2026.
Pharma sector stocks today, July 6: Panacea Biotec surges 2.47%, Ajanta Pharma gains 1.48%, Glenmark Pharma up 1.29%
Indian pharmaceutical stocks showed mixed movements in early trading on July 6, 2026. The broader market indices recorded modest gains, with the Nifty 50 up 0.42% at 24,372.30 and the…
Ajanta Pharma receives USFDA EIR for Paithan facility after inspection
Ajanta Pharma informed the stock exchanges that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility loc...
Ajanta Pharma receives US FDA's EIR for Paithan facility inspection
Ajanta Pharma Limited has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility located in Paith...
Pharma sector stocks today, June 30: Ajanta Pharma falls 2.96%, Dr. Reddy's Lab down 1.77%, Aurobindo Pharma up 1.41%
The pharma sector showed mixed movement on June 30, 2026, during morning trade. The BSE Healthcare index was up 0.15% at 49,094.24, while the broader market indices remained in negative…
Top losers in morning trade: gujarat state petronet at ₹268.35 down 7.13%, valor estate at ₹114.34 down 2.87%, ajanta pharma at ₹3,045.00 down 2.75%
The Indian stock market displayed a mixed performance in the morning session on 15 June 2026, with the SENSEX rising by 1.52% to 76,672.22 and the NIFTY 50 climbing 1.45%…
Pharma sector stocks today June 15: Orchid Pharma up 4.90%, Strides Pharma gains 3.86%, Ajanta Pharma falls 2.32%
Pharma stocks traded mixed on June 15, 2026, during the early morning session, with gains and losses spread across the sector even as the broader market surged. The Nifty 50…
Ajanta Pharma to hold 47th annual general meeting on 16th July 2026
Ajanta Pharma has announced that its 47th Annual General Meeting (AGM) is scheduled for Thursday, 16th July 2026, at 11:00 a.m. (IST). The meeting will be conducted through Video Conferencing…
Pharma sector stocks today, June 9: Panacea Biotech surges 9.11%, Divis Laboratories up 3.46%, Ajanta Pharma gains 1.86%
Pharma stocks traded largely in positive territory on June 9, 2026, during the morning session, with most stocks posting gains. The broader market was stable, with the Nifty 50 up…
Pharma sector stocks fall today, June 2: Wockhardt crashes 6.23%, Torrent Pharma down 2.06%, Ajanta Pharma down 1.96%
Pharmaceutical stocks traded mostly lower during the morning session on June 2, 2026. The BSE Healthcare index declined 0.81% to 46,088.65.The Nifty 50 was down 0.31% at 23,309.85, and the…
Pharma sector stocks rises today, May 6: Wockhardt jumps 7.16%, Ajanta Pharma surges 3.56%, Lupin up 1.60%
Indian pharmaceutical stocks traded higher in the early session on May 6, 2026. The Nifty Pharma index stood at 23,732.2, up 0.7%. The broader market also showed modest gains, with…
Ajanta Pharma Transcript: Q4 25/26
Revenue and profit saw double-digit growth, with strong performance across India, U.S., and Africa. FY 2027 guidance targets high-teen revenue growth and 27% EBITDA margin, factoring in higher costs and investments. Geopolitical risks and cost pressures are embedded in outlook.
Ajanta Pharma Slides: Q4 2026
Ajanta Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 5, 2026.
Ajanta Pharma Quarterly report: Q4 2026
Ajanta Pharma has published its Q4 2026 quarterly earnings report on May 5, 2026.
Ajanta Pharma Annual report: Q4 2026
Ajanta Pharma has published its Q4 2026 annual report on May 5, 2026.
Ajanta Pharma announces re-appointment of auditors for FY 2026-27
Ajanta Pharma has announced the re-appointment of its internal, cost, and tax auditors for the financial year 2026-27. The decision was approved at the company's board meeting held on 5th…
Ajanta Pharma grants 1,45,000 stock options and cancels 850 under ESOP plan
Ajanta Pharma has announced the grant of 1,45,000 stock options under its Share Based Incentive Plan 2019. Each option covers one share, with an exercise period of three months from…
Ajanta Pharma Q4 Results: Revenue jumps 21.5% YoY to Rs 1,421.64 crore, net profit up 18.4%
Ajanta Pharma reported a strong performance for the fourth quarter of FY26, with healthy year-on-year growth across revenue and profitability, supported by steady operational momentum. Revenue from op...
Ajanta Pharma receives five observations from US FDA after facility inspection
Ajanta Pharma has announced that the US Food and Drug Administration (FDA) concluded an inspection at its manufacturing facility in Paithan, Maharashtra. The inspection, which took place from 13th Apr...
Pharma sector stocks today, April 21: Wockhardt surge 2.08%, Natco Pharma down 1.86%, Ajanta Pharma up 1.10%
The Indian pharma sector opened on a mixed note on April 21, 2026 (as of 9:43 AM). The S&P BSE Healthcare Index stood at 43,475.50, up 0.23%, while the NIFTY…